Annals of Hepatology · Nov 7, 2026

Evolution and impact of sarcopenia and myosteatosis in the context of liver transplantation

By Villeret F, Herreros V, Cayot B et al.

Introduction and Objectives Sarcopenia and myosteatosis have a well-documented adverse impact on survival in liver cirrhosis patients. This study aimed to assess the prevalence and risk factors associated with muscle impairment before liver transplantation (LT), their evolution after LT, and to determine their prognostic value. Patients and Methods All cirrhotic patients listed for LT at our center between 2006 and 2010 were included. Sarcopenia and myosteatosis were assessed on transverse L3 CT images at LT listing and at 12 (M12), 60, 120, and 180 months after LT. Results The study population consisted of 198 patients, 75.3% of whom were men, and 149 underwent LT. At LT listing, sarcopenia was diagnosed in 45.5% of patients and myosteatosis in 36.5% and 20.1% had both sarcopenia and myosteatosis. One year after LT, 56.1% of patients had persistent sarcopenia and 15.3% had de novo sarcopenia. Sarcopenia significantly improved at M12 post-LT (p=0.034). Post-LT patient survival was 89.2%, 76.3%, and 59.3% at 1, 5, and 10 years respectively. In multivariate analysis, at LT listing, MELD score ≥ 25 (HR: 2.549; p=0.001), sarcopenia (HR: 1.749; p=0.004) and myosteatosis (HR: 1.630; p=0.012) were found to be independent risk factors for overall mortality. The effects of sarcopenia and myosteatosis were additive: overall survival was significantly reduced in patients with both sarcopenia and myosteatosis compared to patients with isolated sarcopenia/myosteatosis (p=0.001). Conclusions Sarcopenia and myosteatosis are common in cirrhotic patients listed for LT, persist after LT, and have a major and independent impact on overall mortality.

doi.org/10.1016/j.aohep.2026.102481Open accessPubMed 42998818Biomarkers

AgingResearch.News